These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35912272)

  • 1. Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma.
    Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Liu G; Yao W
    Front Oncol; 2022; 12():922127. PubMed ID: 35912272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.
    Zheng A; Liu J; Liu Z; Mo Z; Fu Y; Deng Y; Jiang Y
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):58. PubMed ID: 38294686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
    Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
    Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma.
    Sun X; Xu J; Xie L; Guo W
    Int J Gen Med; 2022; 15():7581-7591. PubMed ID: 36196372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
    Xu B; Pan Q; Pan H; Li H; Li X; Chen J; Pang D; Zhang B; Weng D; Peng R; Fang M; Zhang X
    EClinicalMedicine; 2023 Oct; 64():102240. PubMed ID: 37767191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
    Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
    Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
    Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
    Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study.
    Wu J; Li C; Liu B; Liu Q; Liu D; Wang Z; Wang X; Jia W; Tian X; Hao C
    Ann Transl Med; 2023 Mar; 11(5):212. PubMed ID: 37007540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
    Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial.
    Wang ZM; Zhuang RY; Guo X; Zhang CL; You Y; Chen LS; Liu WS; Zhang Y; Luo RK; Hou YY; Lu WQ; Zhou YH
    Clin Cancer Res; 2022 Dec; 28(24):5290-5296. PubMed ID: 36228149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
    Cai M; Zhu J; Zhou G
    Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
    Bilici A; Koca S; Karaagac M; Aydin SG; Eraslan E; Kaplan MA; Ocak B; Goksu SS; Paydas S; Akgul F; Derin S; Ergun Y; Yekeduz E; Erol C; Ozyukseler DT; Demiray AG; Karaca M; Guc ZG; Menekse S; Cinkir HY; Gumusay O; Sakin A; Ozkul O; Demir H; Erdem D; Besiroglu M; Unal OU; Acar R; Koral L; Sahin S; Sakalar T; Bahceci A; Ozveren A; Gunaydin UM; Seker MM; Sunar V; Dal P; Artac M; Turhal S
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8243-8253. PubMed ID: 37067546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era.
    Zhang RS; Liu J; Deng YT; Wu X; Jiang Y
    Cancer Med; 2022 Jun; 11(11):2271-2283. PubMed ID: 35191609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
    Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study.
    Zhang XY; Liu J; Deng YT; Jiang Y
    Anticancer Drugs; 2022 Jan; 33(1):e519-e524. PubMed ID: 34282747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.
    Dickson MA; D'Adamo DR; Keohan ML; D'Angelo SP; Carvajal RD; Gounder MM; Maki RG; Qin LX; Lefkowitz RA; McKennon OR; Hirst CM; Schwartz GK; Tap WD
    Sarcoma; 2015; 2015():532478. PubMed ID: 26074722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J; Deng YT; Jiang Y
    Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line Anlotinib Treatment for Soft Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-label, Single-arm, Phase 2 Clinical Trial.
    Li T; Dong Y; Wei Y; Wang S; Liu Y; Chen J; Xiong W; Lin N; Huang X; Liu M; Yan X; Ye Z; Li B
    Clin Cancer Res; 2024 Mar; ():. PubMed ID: 38483309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
    Liu Y; Ge Q; Xu S; Li K; Liu Y
    Front Oncol; 2022; 12():942678. PubMed ID: 36059654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.